Background: Chronic obstructive pulmonary disease (COPD) is characterized by marked phenotypic heterogeneity. Most previous studies have focused on COPD subjects with FEV 1 < 80% predicted. We investigated the clinical and genetic heterogeneity in subjects with mild airflow limitation in spirometry grade 1 defined by the Global Initiative for chronic Obstructive Lung Disease (GOLD 1). Methods: Data from current and former smokers participating in the COPDGene Study (NCT00608764) were analyzed. K-means clustering was performed to explore subtypes within 794 GOLD 1 subjects. For all subjects with GOLD 1 and with each cluster, a genome-wide association study and candidate gene testing were performed using smokers with normal lung function as a control group. Combinations of COPD genome-wide significant single nucleotide polymorphisms (SNPs) were tested for association with FEV 1 (% predicted) in GOLD 1 and in a combined group of GOLD 1 and smoking control subjects. Results: K-means clustering of GOLD 1 subjects identified putative "near-normal", "airwaypredominant", "emphysema-predominant" and "lowest FEV 1 % predicted" subtypes. In nonHispanic whites, the only SNP nominally associated with GOLD 1 status relative to smoking controls was rs7671167 (FAM13A) in logistic regression models with adjustment for age, sex, packyears of smoking, and genetic ancestry. The emphysema-predominant GOLD 1 cluster was nominally associated with rs7671167 (FAM13A) and rs161976 (BICD1). The lowest FEV 1 % predicted cluster was nominally associated with rs1980057 (HHIP) and rs1051730 (CHRNA3). Combinations of COPD genome-wide significant SNPs were associated with FEV 1 (% predicted) in a combined group of GOLD 1 and smoking control subjects. Conclusions: Our results indicate that GOLD 1 subjects show substantial clinical heterogeneity, which is at least partially related to genetic heterogeneity. ª
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide, which is characterized by persistent and usually progressive airflow limitation. While cigarette smoking is a wellknown risk factor, large variability in the response to cigarette smoke exists among individuals [1] . Although chronic bronchitis and emphysema are two classic diseaserelated characteristics of COPD [2] , many different COPDrelated phenotypes have been suggested [3e9] . COPD subjects with the same age, body mass index (BMI), and lung function exhibit different levels of dyspnea, exacerbation frequency, exercise capacity, severity of emphysema, and quality of life [10, 11] . There have been many reports investigating heterogeneity of COPD patients [3e11] . However, most of them have focused on subjects with an FEV 1 < 80% predicted [6,7,10e14] . Studies of COPD patients with relatively preserved FEV 1 are rare [15, 16] , yet these subjects make up a large proportion of subjects with COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [17, 18] . The FEV 1 /FVC ratio normally falls with increasing age [19] , so some fraction of individuals with reduced FEV 1 /FVC but normal FEV 1 are likely healthy [20, 21] . However, some GOLD 1 subjects will likely progress to moderate and even severe COPD. Identification of the clinical, imaging, and genetic characteristics of GOLD 1 subjects with progressive disease could provide opportunities for early treatment interventions.
To begin to understand the epidemiology and genetics of COPD heterogeneity among individuals with mild airflow limitation, we investigated subjects with spirometry grade 1 defined by GOLD [17] in the COPDGene Study. Our hypothesis was that there is identifiable heterogeneity within GOLD 1 subjects, with some individuals having significant COPD and others being healthy. We also hypothesized that there will be an association of previously described single nucleotide polymorphisms (SNPs) [22e26] with COPD-related phenotypes in GOLD 1 subjects.
Methods

Study population
COPDGene (clinicaltrials.gov Identifier NCT00608764) is a multicenter study designed to investigate the underlying genetic determinants of COPD. Study details have been described [27] and all protocols and questionnaires are available at http://www.copdgene.org. All subjects were self-identified non-Hispanic white (NHW) or African American (AA) between 45 and 80 years old and had at least 10 pack-years of cigarette smoking. Institutional review board approval was obtained at each of the 21 participating clinical centers; all subjects provided written informed consent. Subjects completed questionnaires, pre-and postbronchodilator spirometry with quality control review, 6-min walk test, and volumetric computed tomography (CT) of the chest at both inspiration and expiration.
Variable definitions
Percent predicted values and lower limits of normal (LLN) were calculated using post-bronchodilator spirometric values [19] . Subjects with GOLD spirometry grade 1 were defined as having post-bronchodilator FEV 1 ! 80% predicted with FEV 1 / FVC < 0.7, and smoking controls were defined as smokers with normal lung function (post-bronchodilator FEV 1 ! 80% with FEV 1 /FVC ! 0.7). Among GOLD 1 subjects, LLN-defined subgroups were defined as follows: LLN-COPD subjects had FEV 1 / FVC < LLN and LLN-normal subjects had FEV 1 /FVC ! LLN based on Hankinson prediction equations [19] .
Quantitative CT lung density measurements were performed using Slicer (Version 2, www.slicer.org). Percent emphysema was calculated as the percentage of voxels within the lung with an attenuation < À950 Hounsfield units (HU) at full inspiration [% low attenuation area (LAA) À 950 insp ] [28] . For percent emphysema, we used <5% as a normal limit based on measurements from healthy non-smoking controls and !10% as a criteria of significant emphysema [29, 30] . Airway analysis was performed using the Pulmonary Workstation Plus (VIDA Diagnostics, Inc., Coralville, IA). In each segmental bronchus, the wall area (WA) and lumen area (LA) were measured. The segmental wall area% was defined as 100 Â WA/(WA þ LA). The square root of the wall area of a hypothetical 10 mm internal perimeter airway (Pi10) was used as another measure of airway disease. Additional variable definitions are available in e-Appendix 1.
Epidemiological analysis
Comparisons of continuous variables between groups were made using a Wilcoxon rank sum test or KruskaleWallis test, as appropriate. Chi-square or Fisher's exact tests were used for categorical variables. Statistical analyses were performed using R (2.15.1). A Venn diagram was generated using an automatic area-proportional Euler diagram drawing tool available at http://www.eulerdiagrams.org/ eulerAPE/(eulerAPE 2.0.3., University of Kent, Canterbury, UK).
Cluster analysis
K-means clustering analyses were performed on a subset of GOLD 1 subjects with complete data for three key input variables which were selected to capture information related to airflow, emphysema, and airway disease: postbronchodilator FEV 1 % predicted, %LAAÀ950 insp , and segmental wall area%. We used normalized mutual information [31] to determine the optimal number of clusters; clustering and candidate gene testing were performed separately in NHW and AA subjects using R (2.15.1).
Genetic analysis
Genome-wide SNP genotyping data were obtained on the Illumina (San Diego, CA) OmniExpress platform with additional genotypes imputed using MaCH [32] and minimac [33] and 1000 Genomes [34] Phase I v3 using European (EUR) or cosmopolitan reference panels for the NHWs and AAs, respectively. Genome-wide association testing for binary GOLD 1 status under an additive model, adjusting for age, sex, pack-years of cigarette smoking, and principal components for genetic ancestry was performed separately in NHW and AA subjects using PLINK [35] with smokers with normal lung function as a control group. Fixed-effects meta-analysis [36] of these two racial groups was performed using METAL (version 2010-08-01) [37] and R 2.15.1 (www.r-project.org) with the meta-package. In addition to the genome-wide analysis, SNPs within genomic regions which have previously been identified to be associated with moderate-to-severe COPD or emphysema at genome-wide significance were further investigated. The single most significant previously reported SNP from the HHIP, FAM13A, RAB4B, and BICD1 regions was included; for the chromosome 15q25 region, which may contain multiple COPD susceptibility loci, two SNPs were selected. These COPD genome-wide significant SNPs were used in genetic association analysis comparing GOLD 1 subjects to smoking controls, and each GOLD 1 cluster to smoking controls; in addition, genetic association analysis with FEV 1 (% predicted) was performed in GOLD 1 and combined subjects of GOLD 1 and smoking controls. Bronchodilator responsiveness was considered positive if the change in FEV 1 was !200 mL and ! 12% predicted following administration of short acting inhaled beta-agonist. For bronchodilator responsiveness, n Z 783. For TLC CT , % emphysema, and segmental wall area%, n Z 760. For % gas trapping, n Z 678. For Pi10, n Z 750. For respiratory medication use, n Z 782. a Thirteen subjects who indicated that they had an ER visit or hospitalization in the past year but who did not respond affirmatively to the question "Have you had a flare-up of your chest trouble in the last 12 months" were included in the exacerbation group.
Results
Epidemiology
The number of GOLD 1 subjects enrolled in COPDGene was 794. Comparisons between GOLD 1 subjects with LLN-COPD and those with LLN-normal are summarized in Table 1 . Subjects meeting both GOLD 1 and LLN-COPD criteria, as expected, were younger; however, we also found higher proportions of AAs and current smokers, decreased BMI and increased total lung capacity measured by CT, as well as an increased prevalence of chronic bronchitis, relative to LLNnormal subjects. While MMRC dyspnea score of LLN-COPD subjects was higher, their mean six-minute walk distance was longer than that of LLN-Normal. However, there were no differences in percentages of emphysema and gas trapping, segmental wall area%, Pi10, exacerbation frequency, history of severe exacerbations, and frequency of respiratory medication use between GOLD 1 LLN-COPD and LLN-Normal subjects. The prevalence of comorbidities in these two groups of GOLD 1 subjects was similar except for diabetes mellitus, hypertension and hyperlipidemia, which were more prevalent in LLN-normal subjects likely related to their older mean age. Physician-diagnosed asthma and COPD were reported in 13.5% and 31% of all GOLD 1 subjects, respectively, and 6.5% received a diagnosis of both asthma and COPD. There were no differences in the rates of physician-diagnosed asthma or physician-diagnosed COPD between the two LLN-defined GOLD 1 groups. Table 2 shows comparisons according to the presence or absence of any respiratory exacerbation in the year prior to study participation among GOLD 1 subjects. Subjects with a history of any respiratory exacerbation were more likely to be female, and they had increased segmental wall area%, higher MMRC dyspnea score, and increased prevalence of chronic bronchitis and physician-diagnosed asthma compared to those without history of exacerbation. Except for oral corticosteroids, all respiratory medications were Bronchodilator responsiveness was considered positive if the change in FEV 1 was !200 mL and ! 12% predicted following administration of short-acting inhaled beta-agonist. For bronchodilator responsiveness, n Z 598. For % gas trapping, n Z 549. For Pi10, n Z 600. For respiratory medication use, n Z 599.
more frequently used in those with an exacerbation history. However, the prevalence of measured comorbidities did not show any differences between these two groups. Table 3 compares GOLD 1 subjects with and without significant emphysema. Among subjects with significant emphysema, there were more males, fewer current smokers, higher pack-years of smoking, lower BMI, lower segmental wall area%, and lower Pi10 compared with those without significant emphysema. Tiotropium was more frequently used in subjects with higher% emphysema. There were no differences in frequency of exacerbation and prevalence of comorbidities between these groups except for coronary artery disease. These epidemiological analyses suggest substantial heterogeneity within the GOLD 1 group, which is illustrated in Fig. 1 .
Cluster analysis
To further explore heterogeneity in GOLD 1 subjects, we performed cluster analysis. The subset of GOLD 1 subjects with complete data for FEV 1 % predicted, % emphysema, and segmental wall area% included in the cluster analysis (n Z 760) did not differ from the full cohort of GOLD 1 subjects with respect to mean age, pack-years of cigarette smoking, BMI, or distribution by gender or current smoking status. Normalized mutual information analysis demonstrated high cluster reproducibility for k Z 4 clusters (Table  E1) . The results of k-means clustering in NHW subjects with GOLD 1 are summarized in Table 4 . Members of cluster 1 demonstrated the highest post-bronchodilator FEV 1 % predicted; we refer to this cluster as a putative "nearnormal subtype". Members of cluster 2 have the youngest age, the highest BMI and segmental wall area%, the highest proportion of chronic bronchitis and bronchodilator responsiveness, and the shortest 6 min walk distance; we refer to this cluster as a putative "airway-predominant subtype". Members of cluster 3 have the oldest age, the lowest BMI, the highest% emphysema, % gas trapping, and MMRC dyspnea score, the lowest rate of current smoking but the highest pack-years, and the lowest resting O 2 saturation; we refer to this cluster as the "emphysemapredominant subtype". Finally, members of cluster 4 show the lowest post-bronchodilator FEV 1 % predicted and rate of bronchodilator responsiveness; we refer to this as the "lowest FEV 1 % predicted subtype". Table E2 shows the results of k-means clustering in AA GOLD 1 subjects on the left and the results of clustering AA GOLD 1 subjects by using clustering centers of NHW subjects on the right. The reproducibility rate of assigning AA subjects using these two methods was 75%.
Genetics
After genotyping and quality control, 587 subjects with GOLD 1 and 2534 smoking controls were included for genetic analysis of NHWs, and 161 GOLD 1 subjects and 1749 smoking controls were included for genetic analysis of AAs. GWAS of all GOLD 1 subjects relative to smoking controls for each of NHWs and AAs did not include any SNPs that reached the genome-wide significance threshold (p < 5 Â 10 À8 ) (Table E3 and E4, Fig. E1 and E2 ). The most significantly associated SNPs for all GOLD 1 subjects relative to smoking controls were: rs6084592 on chromosome 20p13 (RNF24, p Z 1.06 Â 10 À7 ) in NHW and rs114095670 on 9p13.3 (RECK, p Z 5.92 Â 10 À8 ) in AA. Neither a metaanalysis of NHWs and AAs nor additional analyses with adding current/former smoking status as an adjustment variable led to any SNPs meeting genome-wide significance.
GWAS of each GOLD 1 cluster relative to smoking controls was performed separately in NHW and AA subjects; only SNPs with minor allele frequencies (MAFs) above 5% were analyzed. There were only two genome-wide significant SNPs, rs7268680 near to KIF16B on 20p12.1 with MAF of 0.09 (p Z 1.67 Â 10 À8 ) in the lowest FEV 1 GOLD 1 cluster of NHWs (n Z 219) and rs17669292 near to TAF13 on 1p13.3 with MAF of 0.1 (p Z 3.35 Â 10 À8 ) in the lowest FEV 1 GOLD 1 cluster of AAs (n Z 66). Further replication of these cluster-specific findings will be required, since the sample sizes are quite small for a GWAS.
Since the GWAS results in our relatively small sample size of GOLD 1 subjects were not genome-wide significant, we assessed genetic variants associated with COPD or emphysema previously reported to be genome-wide significant in the literature including rs7671167 (4q22, FAM13A); rs1980057 (4q31, HHIP); rs13180 and rs1051730 (15q25, IREB2/CHRNA3); rs161976 (12p11, BICD1); and rs7937 (19q13, RAB4B) [22e26]. These SNPs were examined for associations with GOLD 1 relative to smoking controls, GOLD 1 cluster relative to smoking controls, and postbronchodilator FEV 1 % predicted among combined subjects with GOLD 1 and smoking controls or only GOLD 1 subjects. In NHWs, the only SNP nominally associated with GOLD 1 status relative to smoking controls was rs7671167 (FAM13A) in both univariate and multiple logistic regression models with adjustment for age, sex, pack-years of cigarette smoking and genetic ancestry principal components (Table  5 ). In the analysis of GOLD 1 clusters, we noted a general lack of genetic associations in the near-normal and airwaypredominant clusters; however, nominally significant associations were found between the emphysema-predominant GOLD 1 cluster and SNPs near FAM13A (rs7671167) and BICD1 (rs161976). The lowest FEV 1 % predicted cluster was associated with rs1980057 (HHIP) and rs1051730 (CHRNA3) ( Table 6 ). While two SNPs, rs1051730 (CHRNA3) and rs7937 (RAB4B), were associated with post-bronchodilator FEV 1 % predicted in the combined group of GOLD 1 and smoking control subjects in both univariate and multiple linear regression models with adjustment for pack-years of cigarette smoking and the genetic ancestry principal components, rs1980057 (HHIP) was associated with FEV 1 % predicted in subjects with GOLD 1 in only univariate linear regression analysis (Table 7) .
In AAs, the only SNP nominally associated with GOLD 1 status relative to smoking controls was rs1051730 (CHRNA3) in both univariate and multiple logistic regression models (Table E5 ). In the analysis of AA GOLD 1 clusters compared to AA smoking controls, nominally significant association was found between the near-normal GOLD 1 cluster and rs1051730 (CHRNA3) ( Table E6 ). In AAs, there were no SNPs associated with post-bronchodilator FEV 1 % predicted in the combined group of GOLD 1 and smoking control subjects or in only GOLD 1 subjects.
In NHWs but not in AAs, the number of COPD risk alleles based on four previously reported COPD genome-wide significant associations, consisting of rs7671167 (FAM13A), Table 4 Results of k-means clustering for k Z 4 clusters in non-Hispanic white subjects with GOLD 1 (N Z 594). rs1980057 (HHIP), rs1051730 (CHRNA3), and rs7937 (RAB4B), were negatively associated with postbronchodilator FEV 1 % predicted (p < 0.001) and positively associated with % emphysema among combined subjects with GOLD 1 and smoking controls (p Z 0.022, Fig. 2 ), but not in only GOLD 1 subjects.
Discussion
This study demonstrates that substantial phenotypic heterogeneity of COPD exists even in individuals with mild airflow limitation. We also found that genetic variants previously associated with moderate-to-severe COPD demonstrate evidence for genetic associations with reduced lung function and clustering-derived clinical subtypes of GOLD 1 subjects. Our findings provide suggestive evidence that at least part of the observed phenotypic heterogeneity in GOLD 1 subjects is related to genetic variants. Previous studies that have focused on subjects with mild airflow obstruction are rare. Recently, a physiological study showed that the respiratory system reached its physiologic limit in mild COPD at a lower peak work rate and ventilation Table 5 Logistic regression analyses of previously identified COPD GWAS SNPs with GOLD 1 (n Z 587) relative to smokers with normal lung function (n Z 2534) among non-Hispanic white subjects. than in healthy participants [16] . Although most of the GOLD 1 subjects in our study did not have severe emphysema or functional limitations, a small number of GOLD 1 subjects had severe emphysema (>20%) and even resting hypoxemia. We found clinical heterogeneity of GOLD 1 population in various aspects. Firstly, we compared GOLD 1 subjects with LLN-COPD to those with LLN-normal. Those with LLN-COPD had some evidence for increased respiratory symptoms compared to LLN-normal subjects, based on their higher mean MMRC score and increased prevalence of chronic bronchitis, but they had better exercise performancedwhich may relate to their younger mean age. We found that GOLD 1 subjects with a history of respiratory exacerbations had increased respiratory symptoms (chronic bronchitis and dyspnea) and increased respiratory medication use. The GOLD 1 subjects with a history of respiratory exacerbations exhibited thicker airway walls and increased prevalence of chronic bronchitis compared to those without an exacerbation in the year before study enrollment. Previously, many studies have reported increased risk of COPD exacerbations in patients with chronic bronchitis [7, 38, 39] . Also, GOLD 1 subjects with a history of respiratory exacerbations reported physician-diagnosed asthma more frequently compared to those without, which is consistent with a previous study demonstrating increased frequency of exacerbations in patients with moderate-to-severe COPD and a history of physician-diagnosed asthma compared to those without a history of physician-diagnosed asthma [40] . In order to provide insights into the substantial clinical heterogeneity which we observed, we selected postbronchodilator FEV 1 % predicted, % emphysema, and segmental wall area% for cluster analysis; these variables were chosen based on many previous studies demonstrating that these phenotypes represent key components of COPD, including airflow limitation, parenchymal destruction, and airway disease, respectively [5, 28, 30, 41, 41, 42] . K-means clustering showed four discrete subgroups, which were similar in NHW and AA subjects. The airway-predominant cluster is characterized by poor exercise performance and quality of life in spite of relatively young age, low percentages of emphysema and gas trapping, and high rate of post-bronchodilator response, which may be related to their high prevalence of chronic bronchitis and increased airway wall thickness. While airway-and emphysema-predominant GOLD 1 clusters represent two classic phenotypes [2] , the near-normal cluster may represent individuals who have a reduced FEV 1 /FVC but are otherwise well. Of interest, their mean FVC% predicted value exceeds the normal upper limit (122.4%) in contrast with a normal mean FEV 1 % predicted (105.9%).
Even though GWASs of GOLD 1 relative to smoking controls revealed no genome-wide significant associations in both NHWs and AAs, the top SNP in AA subjects, rs114095670, was nearly genome-wide significant and is located within RECK, a negative regulator of MMP9 [43, 44] , which was previously reported by our group to be regulated by HHIP in human bronchial epithelial cells [45] . In both NHWs and AAs, the airway-predominant GOLD 1 cluster did not show any significant associations with previously identified COPD risk alleles. Interestingly, SNPs nominally associated (p < 0.05) with the emphysema-predominant NHW GOLD 1 cluster relative to smoking controls were different from those associated with the lowest FEV 1 % predicted cluster. These results support the concept that clinical heterogeneity of COPD may be closely related to genetic heterogeneity. An SNP associated with the emphysemapredominant NHW GOLD 1 cluster, rs161976 (BICD1), was previously demonstrated in GWAS for emphysema in COPD patients with FEV 1 < 80% predicted [24] . The lowest FEV 1 % predicted subgroup had the lowest rate of postbronchodilator response, suggesting fixed airway obstruction. Each subtype may have, at least in part, a different set of genetic susceptibility determinants. Even though the known COPD genome-wide significant SNPs do not provide a complete explanation for COPD, the number of risk alleles at four previously reported COPD GWAS loci correlated with post-bronchodilator FEV 1 % predicted in the group of COPDGene subjects with normal FEV 1 values (smoking controls and GOLD 1). Thus, we reconfirmed that these COPD risk alleles, identified in GWAS of moderate-to-severe COPD [22, 23, 25, 26] , likely play a role in mild COPD as well.
Our study is the largest detailed description of GOLD 1 reported to date and demonstrates a relationship between Figure 2 Mean (A) post-bronchodilator FEV 1 % predicted (N Z 3121) and (B) percent emphysema (N Z 2984) according to the number) of known COPD risk allele for rs7671167 (FAM13A), rs1980057 (HHIP), rs1051730 (CHRNA3) and rs7937 (RAB4B) in nonHispanic white subjects with GOLD 1 or normal lung function. genetic variation and clinical heterogeneity. However, our study did have several important limitations. Despite the size of our study, the number of subjects is still small in the context of GWAS and likely limits our ability to detect novel genetic variants. It is not yet clear whether known predictors of lung function decline or future respiratory exacerbations in moderate-to-severe COPD will be applicable for GOLD 1. Whether our four clusters will demonstrate stability or progression to advanced COPD stages will need to be addressed with longitudinal studies.
Clinically useful subtypes in subjects with mild airflow limitation should be helpful for individualized treatment and/or risk prediction. The currently available evidence is not adequate to create such a clinically useful set of GOLD 1 subtypes with certainty; replication of our proposed subtypes in other study populations will be necessary. In addition, genetic markers may be useful to define GOLD 1 subtypes; for example, our results suggest that an NHW subject with risk alleles for both FAM13A and BICD1 might have an increased risk of emphysema, while an NHW subject with risk alleles for HHIP and CHRNA3 might experience accelerated decline of FEV 1 . These conjectures will also need to be validated in other study populations.
In summary, we have reported epidemiological and radiographic characteristics of GOLD 1 subjects, explored clinically relevant putative subtypes, and analyzed genetic associations with these subtypes. The current study has clearly shown substantial clinical heterogeneity of GOLD 1 subjects; our results also suggest that different genetic determinants may influence different GOLD 1 subtypes. Future work including larger numbers of GOLD 1 subjects for genetic association studies as well as longitudinal follow-up of GOLD 1 subjects may provide new insights into COPD progression and therapeutic approaches.
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